Previous preclinical studies show that anti-apoptotic Bcl-2 family proteins promote resistance to standard of care breast cancer therapies, including endocrine inhibitors13–16, HER2 inhibitors40, and chemotherapies41–43. Here, ERBB2 is linked to breast carcinoma.